A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

BACKGROUND: Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy. METHODS: Eligible patients (3–6 per cohort) had extensive-stage SCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappori, A A, Schreeder, M T, Moezi, M M, Stephenson, J J, Blakely, J, Salgia, R, Chu, Q S, Ross, H J, Subramaniam, D S, Schnyder, J, Berger, M S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305978/
https://www.ncbi.nlm.nih.gov/pubmed/22333598
http://dx.doi.org/10.1038/bjc.2012.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305978/
https://www.ncbi.nlm.nih.gov/pubmed/22333598
http://dx.doi.org/10.1038/bjc.2012.21

Ejemplares similares